ROCK mediates the inflammatory response in thrombin induced microglia

Neuroscience Letters

Volumn 554, Issue , 2013, Pages 82-87

  Cui, Guiyun ^a   Zuo, Tao ^b   Zhao, Qiuchen ^a   Hu, Jinxia ^a   Jin, Peisheng ^a   Zhao, Hui ^c   Jing, Jia ^a   Zhu, Jienan ^a   Chen, Hao ^a   Liu, Bin ^a   Hua, Fang ^a   Ye, Xinchun ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Argatroban; Inflammation; Microglia; ROCK; Y 27632

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ARGATROBAN; FLUORESCEIN; LATEX; NITRIC OXIDE; RHO KINASE; THROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; INFLAMMATION; MEDIATOR; MICROGLIA; MICROGLIAL CELL CULTURE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ARGATROBAN; INFLAMMATION; MICROGLIA; ROCK; Y-27632;

AMIDES; ANIMALS; ANTITHROMBINS; CELLS, CULTURED; CEREBRAL CORTEX; FLUORESCEIN; FLUORESCENT DYES; INFLAMMATION; MICROGLIA; MICROSPHERES; NITRIC OXIDE; PHAGOCYTOSIS; PIPECOLIC ACIDS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; THROMBIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884723826     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.08.065     Document Type: Article

References (41)

1. Bernhart E., Kollroser M., Rechberger G., Reicher H., Heinemann A., Schratl P., Hallstrom S., Wintersperger A., Nusshold C., DeVaney T., Zorn-Pauly K., Malli R., Graier W., Malle E., Sattler W. Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture. Proteomics 2010, 10:141-158.
2. Boomkamp S.D., Riehle M.O., Wood J., Olson M.F., Barnett S.C. The development of a rat in vitro model of spinal cord injury demonstrating the additive effects of Rho and ROCK inhibitors on neurite outgrowth and myelination. Glia 2012, 60:441-456.
3. Breslin J.W. ROCK and cAMP promote lymphatic endothelial cell barrier integrity and modulate histamine and thrombin-induced barrier dysfunction. Lymphat. Res. Biol. 2011, 9:3-11.
4. Brouwers H.B., Goldstein J.N. Therapeutic strategies in acute intracerebral hemorrhage. Neurotherapeutics 2012, 9:87-98.
5. Brown G.C., Neher J.J. Eaten alive! Cell death by primary phagocytosis: 'phagoptosis'. Trends Biochem.Sci. 2012, 37:325-332.
6. Carbajal J.M., Gratrix M.L., Yu C.H., Schaeffer R.C. ROCK mediates thrombin's endothelial barrier dysfunction. Am. J. Physiol. Cell Physiol. 2000, 279:C195-C204.
7. Cui G., Ye X., Zuo T., Zhao H., Zhao Q., Chen W., Hua F. Chloroquine pretreatment inhibits toll-like receptor 3 signaling after stroke. Neurosci. Lett. 2013, 548:101-104.
8. Cui G.Y., Gao X.M., Qi S.H., Gillani A., Gao L., Shen X., Zhang Y.D. The action of thrombin in intracerebral hemorrhage induced brain damage is mediated via PKCalpha/PKCdelta signaling. Brain Res. 2011, 1398:86-93.
9. Darenfed H., Dayanandan B., Zhang T., Hsieh S.H.K., Fournier A.E., Mandato C.A. Molecular characterization of the effects of Y-27632. Cell Motil. Cytoskeleton 2007, 64:97-109.
10. Devaraj S., Chan E., Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J. Clin. Endocrinol. Metab. 2006, 91:4489-4496.
11. Escolar G., Bozzo J., Maragall S. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions. Drug Today (Barc.) 2006, 42:223-236.
12. Forgione N., Fehlings M.G. Rho-ROCK inhibition in the treatment of spinal cord Injury. World Neurosurg. 2013, in press.
13. Freyer D., Manz R., Ziegenhorn A., Weih M., Angstwurm K., Döcke W.-D., Meisel A., Schumann R.R., Schönfelder G., Dirnagl U., Weber J.R. Cerebral endothelial cells release TNF-α after stimulation with cell walls of streptococcus pneumoniae and regulate inducible nitric oxide synthase and ICAM-1 expression via autocrine loops. J. Immunol. 1999, 163:4308-4314.
14. Fujii M., Duris K., Altay O., Soejima Y., Sherchan P., Zhang J.H. Inhibition of Rho kinase by hydroxyfasudil attenuates brain edema after subarachnoid hemorrhage in rats. Neurochem. Int. 2012, 60:327-333.
15. Fujimoto S., Katsuki H., Ohnishi M., Takagi M., Kume T., Akaike A. Thrombin induces striatal neurotoxicity depending on mitogen-activated protein kinase pathways in vivo. Neuroscience 2007, 144:694-701.
16. Gavard J., Gutkind J.S. Protein kinase C-related kinase and ROCK are required for thrombin-induced endothelial cell permeability downstream from G alpha(12/13) and G alpha(11/q). J. Biol. Chem. 2008, 283:29888-29896.
17. Gosens R., Schaafsma D., Meurs H., Zaagsma J., Nelemans S.A. Role of Rho-kinase in maintaining airway smooth muscle contractile phenotype. Eur. J. Pharmacol. 2004, 483:71-78.
18. He Y., Xu H., Liang L., Zhan Z., Yang X., Yu X., Ye Y., Sun L. Antiinflammatory effect of Rho kinase blockade via inhibition of NF-kappa B activation in rheumatoid arthritis. Arthritis Rheum. 2008, 58:3366-3376.
19. Hirata A., Inatani M., Inomata Y., Yonemura N., Kawaji T., Honjo M., Tanihara H. Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:51-59.
20. Hiroki J., Shimokawa H., Higashi M., Morikawa K., Kandabashi T., Kawamura N., Kubota T., Ichiki T., Amano M., Kaibuchi K., Takeshita A. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J. Mol. Cell. Cardiol. 2004, 37:537-546.
21. Jayaraman T., Berenstein V., Li X., Mayer J., Silane M., Shin Y.S., Niimi Y., Kilic T., Gunel M., Berenstein A. Tumor necrosis factor alpha is a key modulator of inflammation in cerebral aneurysms. Neurosurgery 2005, 57:558-564. (discussion 558-564).
22. Jeske W.P., Fareed J., Hoppensteadt D.A., Lewis B., Walenga J.M. Pharmacology of argatroban. Exp. Rev. Hematol. 2010, 3:527-535.
23. LoGrasso P.V., Feng Y. Rho Kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr. Top. Med. Chem. 2009, 9:704-723.
24. Mueller B.K., Mack H., Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 2005, 4:387-398.
25. Nohria A., Prsic A., Liu P.Y., Okamoto R., Creager M.A., Selwyn A., Liao J.K., Ganz P. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 2009, 205:517-521.
26. Raad M., El Tal T., Gul R., Mondello S., Zhang Z., Boustany R.M., Guingab J., Wang K.K., Kobeissy F. Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma. Electrophoresis 2012, 33:3659-3668.
27. Schmandke A., Schmandke A., Strittmatter S.M. ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. Neuroscientist 2007, 13:454-469.
28. Sharma J.N., Al-Omran A., Parvathy S.S. Role of nitric oxide in inflammatory diseases. Inflammopharmacology 2007, 15:252-259.
29. Sheikh A.M., Nagai A., Ryu J.K., McLarnon J.G., Kim S.U., Masuda J. Lysophosphatidylcholine induces glial cell activation: role of rho kinase. Glia 2009, 57:898-907.
30. 2+ stores during phagocytosis in human neutrophils. Science 1994, 265:1439-1441.
31. Sun X., Minohara M., Kikuchi H., Ishizu T., Tanaka M., Piao H., Osoegawa M., Ohyagi Y., Shimokawa H., Kira J. The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2006, 180:126-134.
32. Villar-Cheda B., Dominguez-Meijide A., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol. Dis. 2012, 47:268-279.
33. Vossmerbaeumer U., Kuehl S., Bieback K., Klueter H., Jonas J.B. Cultivation and differentiation characteristics of human limbal progenitor cells. Tissue Cell 2008, 40:83-88.
34. Wang J., Hou J.C., Zhang P., Li D., Zhang C.X., Liu J.X. Geniposide reduces inflammatory responses of oxygen-glucose deprived rat microglial cells via inhibition of the TLR4 signaling pathway. Neurochem. Res. 2012, 37:2235-2248.
35. Wang J.A. Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog. Neurobiol. 2010, 92:463-477.
36. Weinstein J.R., Hong S.Y., Kulman J.D., Bishop C., Kuniyoshi J., Andersen H., Ransom B.R., Hanisch U.K., Moller T. Unraveling thrombin's true microglia-activating potential: markedly disparate profiles of pharmaceutical-grade and commercial-grade thrombin preparations. J. Neurochem. 2005, 95:1177-1187.
37. Wu J., Li J., Hu H., Liu P., Fang Y., Wu D. Rho-kinase inhibitor, fasudil, prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the ischemic penumbra of rat brain. Cell. Mol. Neurobiol. 2012, 32:1187-1197.
38. Xue Z.-w., Shang X.-m., Xu H., Lu S.-h., Dong T.-w., Liang C.-h., Yuan Y. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells. Chinese Med. J. (Engl.) 2012, 125:3332-3335.
39. Yarilina A., Xu K., Chan C., Ivashkiv L.B. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 2012, 64:3856-3866.
40. Ye X., Chopp M., Cui X., Zacharek A., Cui Y., Yan T., Shehadah A., Roberts C., Liu X., Lu M., Chen J. Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats. Exp. Neurol. 2011, 232:299-308.
41. Ye X., Chopp M., Liu X., Zacharek A., Cui X., Yan T., Roberts C., Chen J. Niaspan reduces high-mobility group box 1/receptor for advanced glycation endproducts after stroke in type-1 diabetic rats. Neuroscience 2011, 190:339-345.